Nebhan CA, Cortellini A, Ma W, et al. - In this international cohort study, geriatric patients (aged ≥80 years) treated with immune checkpoint inhibitors (ICIs) for cancer were analyzed and findings showed likely effectiveness as well as a general good tolerability of these agents, though ICI cessation due to immune-related adverse events (irAEs) was more frequent with increasing age.

• A multicenter, international retrospective analysis of 928 geriatric patients (aged ≥80 years) with different tumors managed with single-agent ICIs between 2010 to 2019 from 18 academic centers in the US and Europe.

• For non–small cell lung cancer (NSCLC), melanoma, and genitourinary (GU) tumors, objective response rates were 32.2%, 39.3%, and 26.2%, respectively.

• Median PFS and OS, respectively, were noted to be 6.7 and 10.9 months (NSCLC), 11.1 and 30.0 months (melanoma), and 6.0 and 15.0 months (GU).

• Promising antitumor outcomes in NSCLC, melanoma, and GU tumors were achieved with single-agent ICIs; although no significant difference was observed in rate of irAEs, irAE-related ICI cessation was higher in cases aged 90 years or older, even for lower-grade irAEs.